Skip to main content
An official website of the United States government

erdafitinib

View Patient Information
An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:pan-FGFR tyrosine kinase inhibitor JNJ-42756493
US brand name:Balversa
Code name:JNJ-42756493
Chemical structure:1,2-ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search